Abstract
BackgroundIncreasing evidence indicated a close relationship between aberrant splicing variants and carcinoma, whereas comprehensive analysis of prognostic alternative splicing (AS) profiling in breast cancer (BRCA) is lacking and largely unknown.MethodsRNA-seq data and corresponding clinical information of BRCA patients were obtained and integrated from The Cancer Genome Atlas (TCGA). Then SpliceSeq software was used to assess seven AS types and calculate the Percent Spliced In (PSI) value. Univariate followed by stepwise multivariate Cox regression analyses identified survival associated AS events and constructed the AS signature, which were further sent for enrichment analysis, respectively. Besides, the splicing correlation network was constructed. Additionally, nomogram incorporating AS signature and clinicopathological characteristics was developed and its efficacy was evaluated with respect to discrimination, calibration and clinical utility.ResultsA total of 45,421 AS events were detected, among which 3071 events were found associated with overall survival (OS) after strict filtering. Parent genes of these prognostic events were involved in BRCA-related processes including NF-kappaB and HIF-1 signaling pathway. Besides, the final prognostic signature built with 20 AS events performed well with an area under the curve (AUC) of receiver operating characteristic (ROC) curve up to 0.957 for 5 years. And gene set enrichment analysis (GSEA) also confirmed the candidate 20 AS events contributed to progression of BRCA. Moreover, the nomogram that incorporated 20-AS-event-based classifier, age, pathological stage and Her-2 status showed good calibration and moderate discrimination, with C-index of 0.883 (95% CI, 0.844–0.921). Decision curve analysis (DCA) confirmed more benefit was added to survival prediction with our nomogram, especially in 5 or 8 years with threshold probability up to 80%. Finally, splicing correlation network revealed an obvious regulatory pattern of prognostic splicing factors (SF) in BRCA.ConclusionThis study provided a systematic portrait of survival-associated AS events involved in BRCA and further presented a AS-clinicopathological nomogram, which could be conveniently used to assist the individualized prediction of long-term survival probability for BRCA patients. And a series of bioinformatic analysis provided a promising perspective for further uncovering the underlying mechanisms of AS events and validating therapeutic targets for BRCA.
Highlights
Breast cancer (BRCA) is one of the most common malignant tumors and leading cause of cancer-associated death in women worldwide (DeSantis et al, 2014)
Integrated mRNA splice variant profiles were curated with detailed alternative splicing (AS) events data and clinical information of 645 BRCA patients, among which median follow-up period was 16.7 months
By using SpliceSeq, we totally detected 45,421 splicing events in 10,481 genes, comprised of 17,702 Exon Skip (ES) in 6812 genes, 8595 Alternate Terminator (AT) in 3755 genes, 9112 Alternate Promoter (AP) in 3654 genes, 3731 Alternate Acceptor site (AA) in 2628 genes, 2802 Retained Intron (RI) in 1878 genes, 3246 Alternate Donor site (AD) in 2278 genes and 233 mutually exclusive exons (ME) in 227 genes (Figure 1C). These data showed a single gene might have almost four types of AS events on average, which indicated that different arrangement and combination of splicing types held great potential responsible for transcriptome diversity
Summary
Breast cancer (BRCA) is one of the most common malignant tumors and leading cause of cancer-associated death in women worldwide (DeSantis et al, 2014). It was widely accepted that dysregulation of gene expression (Cruz et al, 2018), copy number variation (Long et al, 2013), and DNA methylation (Visvanathan et al, 2017) were involved in the initiation and progression of BRCA. These studies, with promising results, were mainly confined to transcriptional level while systematic analysis of splicing variant on transcript architecture is always ignored. Increasing evidence indicated a close relationship between aberrant splicing variants and carcinoma, whereas comprehensive analysis of prognostic alternative splicing (AS) profiling in breast cancer (BRCA) is lacking and largely unknown
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.